Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial

Key Points

• To assess the effectiveness of lactoferrin in reducing febrile neutropenia in children undergoing chemotherapy for hematologic malignancies.
• Randomized, placebo-controlled trial
• Inclusion of children with hematologic malignancies
• Administration of lactoferrin vs. placebo during chemotherapy
• Significantly reduced episodes of febrile neutropenia in the lactoferrin group
• Improved overall treatment tolerance observed
• No significant adverse effects reported related to lactoferrin use